re-doc
Try for free
Clinical trials / TransparencyPage 1 of 9
Solutions · Clinical trials / Transparency

Clinical trial data anonymization
that keeps reports readable.

Clinical study reports published under EMA Policy 0070 and Health Canada PRCI must have participants’ personal data anonymized. Re-Doc finds participant identifiers across narratives, listings and appendices and replaces them with consistent synthetic data, so the report stays readable for the researchers it is published for.

1. Your documentcsr_narrative.docx
Patient Narrative
Study ABC-301 · Section 14.3.3
Subject1042-0087
InitialsJ.M.K.
Date of birth14 Mar 1961
SiteHôpital Saint-Louis, Paris
Onset02 Aug 2022
Subject 1042-0087 developed grade 3 neutropenia on Day 15 and recovered after dose interruption.
5 pieces of sensitive data foundIdentifiable participant details.
RE-DOC
2. Safe to sharecsr_narrative_anonymized.docx
Patient Narrative
Study ABC-301 · Section 14.3.3
Subject9001-0412
InitialsR.T.L.
Date of birth1961
SiteSite 12, Country A
OnsetDay 15
Subject 9001-0412 developed grade 3 neutropenia on Day 15 and recovered after dose interruption.
Replaced with synthetic dataSynthetic data. Readable and consistent.

Illustrative example with invented data. Your anonymization rules (for example, relative days instead of dates) decide the exact transformations.

0.09Re-identification risk threshold recommended by EMA and Health Canada
2Major transparency regimes: EMA Policy 0070 and Health Canada PRCI
CSRNarratives, listings and appendices handled in one pass
PilotScoped pilot on your own sample sections
The problemPage 2 of 9
§ 02 · The problem

Why clinical document anonymization is slow and costly

Clinical study reports are long, dense and full of participant details in places a simple search misses.

01 · VOLUME

Hundreds of pages per report

A single clinical study report can run to many hundreds of pages once patient narratives, listings and appendices are included. Every participant identifier, date and site detail has to be found and handled consistently across all of them.

02 · UTILITY

Black boxes destroy the science

Studies of published Policy 0070 reports found heavy redaction reduces what researchers can learn from them. Anonymization that replaces or generalises data keeps narratives and tables usable.

RE-DOC
Participant narratives stay readableAdverse event context is keptTables keep their structure
03 · CONSISTENCY

The same participant, many forms

Subject IDs, initials, dates of birth, visit dates and site names appear in prose, tables and headers. If one form is missed, or replaced differently in two places, the report is either unsafe or confusing.

04 · REGULATORY

Two regimes, one team

Sponsors filing in both the EU and Canada face EMA Policy 0070 and Health Canada PRCI. The two agencies have aligned their approach, but the documents still need careful, consistent handling for each release.

How it worksPage 3 of 9
§ 03 · Where Re-Doc fits

Where Re-Doc fits in your disclosure workflow

Re-Doc does the document-level work so your disclosure team can focus on decisions and review.

STEP 1

Prepare scope

Your team defines what must be anonymized, what counts as CCI, and which method applies.

STEP 2

Re-Doc processes

Participant identifiers across narratives, listings and appendices are replaced with consistent synthetic data, or redacted, in the original layout.

STEP 3

Review

Your reviewers check the draft, adjust where needed, and handle CCI and edge cases.

STEP 4

Submit

Your team finalises the documents and the anonymization report for EMA or Health Canada.

Use casesPage 4 of 9
§ 04 · Use cases

Clinical documents Re-Doc handles

The same pipeline covers publication packages and research data sharing.

Use case 01 · Clinical trials / TransparencyEMA · CSR · Module 2.5 / 2.7

Clinical study reports for EMA Policy 0070

Clinical overviews, summaries and study reports prepared for publication on the EMA clinical data site.

  • Participant identifiers replaced consistently
  • Narratives and listings stay readable
Use case 02 · Clinical trials / TransparencyHealth Canada · PRCI

Health Canada PRCI packages

Clinical information prepared for public release through Health Canada’s clinical information portal.

  • Same approach as EMA packages
  • Supports your anonymization report
Use case 03 · Clinical trials / TransparencyVivli · CSDR · Research

Data sharing and secondary research

Clinical documents shared with external researchers or data-sharing platforms, where readability matters as much as privacy.

  • Synthetic data keeps context
  • Consistent across document sets
Anonymization vs redactionPage 5 of 9
Methods

Anonymization vs redaction of clinical trial data

Redaction removes information. Anonymization transforms it so the document keeps its value. Regulators prefer approaches that keep clinical reports useful.

Redaction blacks out or deletes text. It is simple, but heavily redacted narratives and tables tell researchers very little. It remains the right tool for commercially confidential information (CCI).

Anonymization transforms personal data — replacing identifiers with synthetic values, generalising dates to study days or years, grouping rare categories — so the risk of identifying a participant is low while the clinical story stays intact.

Re-Doc supports both: synthetic data replacement for participant data, and permanent redaction where your team marks CCI or other content to remove.

FAQPage 6 of 9
FAQ

Clinical trial anonymization: common questions

01What is clinical trial data anonymization?
It is the process of transforming clinical trial documents, such as clinical study reports, so that trial participants can no longer be identified before the documents are published or shared. Regulators including the EMA and Health Canada require it before clinical reports are made public.
02What does EMA Policy 0070 require?
Policy 0070 requires marketing authorisation applicants to submit clinical reports for publication with participants’ personal data anonymised, and allows commercially confidential information (CCI) to be redacted where justified. An anonymisation report explaining the method is submitted with the documents.
03How does Health Canada PRCI compare with EMA Policy 0070?
Health Canada’s Public Release of Clinical Information (PRCI) has the same goal. The two agencies have aligned their approaches, including a recommended re-identification risk threshold of 0.09 (9%) and a common anonymisation report template.
04Is anonymization the same as redaction for clinical study reports?
No. Redaction removes or blacks out information, which can make narratives and tables unreadable. Anonymization transforms the data (for example, replacing identifiers or generalising values) so that the report keeps its scientific value. The EMA encourages approaches that preserve data utility where possible.
05Does Re-Doc produce the anonymization report or risk score?
No. Re-Doc does the document work: finding participant identifiers and replacing them with consistent synthetic data, or redacting them, across narratives, listings and appendices. Your disclosure team keeps ownership of the risk assessment, CCI decisions and the anonymization report.
06Can we try it on our own documents?
Yes. We run scoped pilots on sample sections of your clinical documents and share results your team can check before any wider use.
ComparisonPage 7 of 9
§ 05 · How Re-Doc compares

Re-Doc next to manual anonymization

Most anonymization is still done by specialist teams working page by page. Re-Doc gives them a consistent first draft.

#Typical tools in the marketRe-DocStatus
01Page-by-page manual review of every narrative and listing.Identifiers found across the whole report in one pass, then reviewed.● Covered
02Black boxes that make narratives hard to read.Consistent synthetic data that keeps the clinical story readable.● Covered
03Inconsistent handling when the same participant appears in many places.The same participant gets the same synthetic identity throughout the report.● Covered
04Separate tools for scanned pages and native files.Native files and scanned pages handled by the same platform.● Covered
SourcesPage 8 of 9
Get startedPage 9 of 9

Run a pilot on your own clinical documents.

Send us sample sections of a clinical study report. We run them through Re-Doc and share results your disclosure team can check before any wider use.